title: Long-term survival in metastatic malignant melanoma: ipilimumab followed by vemurafenib in a patient with brain metastasis.
abstract: A 46-year-old man was diagnosed with brain metastasis after a two-year history of melanoma. Paliative radiotherapy was administered followed by dacarbazine, temozolamide, ipilimumab, stereotactic radiosurgery, ipilimumab reinduction and finally vemurafenib, to which the patient showed objective responses. The patient received vemurafenib for four months and died after progresive disease. Long-term follow-ups after surgery have been reported in the literature. However, in patients with unresectable metastases, outcomes are mostly detrimental. The present patient survived for 40 months after brain metastasis. The unusually long survival observed in the present case indicates the sequential effectiveness of radiotherapy, chemotherapy, ipilimumab, stereotactic radiosurgery and vemurafenib.
authors.affiliation: Department of Medical Oncology, School of Medicine, Gaziantep University, Turkey. ozanbalakan@gantep.edu.tr
authors.forename: Ozan
authors.initials: O
authors.lastname: Balakan
authors.forename: Ali
authors.initials: A
authors.lastname: Süner
authors.forename: Remzi
authors.initials: R
authors.lastname: Yiğiter
authors.forename: Tuba
authors.initials: T
authors.lastname: Balakan
authors.forename: Akif
authors.initials: A
authors.lastname: Sirikçi
authors.forename: Alper
authors.initials: A
authors.lastname: Sevinç
mesh_terms: D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D001932:Brain Neoplasms / Q000556:secondary* / Q000628:therapy*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D006801:Humans; D007211:Indoles / Q000008:administration & dosage*; D000074324:Ipilimumab; D008297:Male; D008545:Melanoma / Q000556:secondary* / Q000628:therapy*; D008875:Middle Aged; D016634:Radiosurgery; D018714:Radiotherapy, Adjuvant; D013449:Sulfonamides / Q000008:administration & dosage*; D013997:Time Factors; D000077484:Vemurafenib
chemical_list: D000911:Antibodies, Monoclonal; D007211:Indoles; D000074324:Ipilimumab; D013449:Sulfonamides; D000077484:Vemurafenib